The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.
Latest Information Update: 20 Aug 2021
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Aug 2021 Results (n=17) assessing acute effects of add- on therapy with the sodium glucose co- transporter 2 inhibitor tofogliflozin to dipeptidyl peptidase (DPP)- 4 inhibitors on 24- hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring (CGM) in patients with type 2 diabetes, published in the International Journal of Clinical Practice.
- 29 Dec 2016 New trial record